samedan logo
 
 
 
spacer
home > ebr > summer 2003 > preclinical juvenile toxicity studies: will it be safe for children?
PUBLICATIONS
European Biopharmaceutical Review

Preclinical Juvenile Toxicity Studies: Will it be Safe for Children?

The last issue of EPC highlighted the growth in paediatric clinical trials and difficulties in performing studies in children. Similar gaps in study cover have become an issue in preclinical studies and it is only in recent years that any studies have focused on the potential effects of direct treatment of young animals and on possible long-term effects.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Audrey Bottomley, David Myers and Chris Willoughby of the Reproductive Studies Group at Huntingdon Life Sciences

Audrey Bottomley is a UK Registered Toxicologist and the Principal Consultant Toxicologist to the Reproductive Studies Group with over 30 years' experience in reproductive and developmental toxicology. She is now primarily concerned with advising external clients and Huntingdon Life Sciences staff on the design and interpretation of reproductive studies.


David Myers is a Senior Study Director and Consultant Toxicologist within the Reproductive Studies Group. He has a PhD in age-related changes in the behaviour and brain of the ageing female mouse and is a specialist in the effects of treatments on behaviour in rodents. David is directly involved with study design management and interpretation in the developing field of behavioural testing.


Chris Willoughby is Head of the Reproductive Studies Group at Huntingdon Life Sciences and has qualifications in pharmacy and toxicology. He has worked in reproductive toxicology with Huntingdon Life Sciences since 1974 and has extensive experience managing studies of all types.

spacer
Chris Willoughby
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Tempus Announces Agreement With Janssen R&D to Leverage AI/ML and Real-World Evidence to Enhance the Discovery and Development of Oncology Therapies

Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research & Development, LLC (Janssen).
More info >>

White Papers

Optimize your Biologicís Analytical Program for Greater Risk Reduction

Merck

Analytical methods are used throughout upstream and downstream processes to help ensure the desired molecule is being produced with the desired purity. In addition to having the right molecule, quality must be confirmed in terms of glycosylation, oxidation, aggregates, activity and concentration. The analytical package must also ensure that all impurities from the manufacturing process and environment are consistently removed.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement